Marijuana Metabolite, Umbilical Cord Tissue, Qualitative
Ordering Recommendation

Detect in utero exposure to cannabis (marijuana) in neonates, consistent with maternal use during approximately the last trimester of pregnancy.

Qualitative Liquid Chromatography-Tandem Mass Spectrometry
1-3 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.) 
Specimen Preparation
Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup or Security Kit for Meconium/Umbilical Drug Detection (ARUP supply #51548) available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787. (Min: 6 inches) 
Storage/Transport Temperature
Unacceptable Conditions
Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed. 
Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year 
Reference Interval
Drugs/Drug ClassesCutoff Concentrations (ng/g)

Interpretive Data
Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry

This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite. Alternative testing is available to detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Absolute Minimum: 6 inches.
Hotline History
View Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
3000257THC-COOH, Cord, Qual61063-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.